# Cizzle Biotechnology: Considerable progress in first year since listing

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-considerable-progress-in-first-year-since-listing-2/4121072884
- Published: 2022-07-15T08:32:49+01:00
- Author: Amilia Stone

**Cizzle Biotechnology plc** (LON:CIZ), focused on cancer diagnostics, was spun 
out of the University of York to exploit the biomarker, variant CIZ1b, for the early
detection of different forms of lung cancer. While implementing this strategy over
the past year, Cizzle’s interest has been broadened to include early detection of
other cancers and companion diagnostic tests that can assist in the development 
and use of personalised medicines. In the 12 months since listing, Cizzle has secured
key partners to generate monoclonal antibodies (mAb) and reagents for a commercial
test, and signed licensing and royalty deals.

 * **Strategy:** Cizzle Biotechnology is a diagnostic company that is progressing
   a biomarker diagnostic assay, which aims to deliver a simple blood test for lung
   cancer that can pick up the disease earlier to improve the chances of survival,
   and to greatly reduce the need for unnecessary follow-up tests and tissue biopsies.
 * **Progress:** Since listing, Cizzle has generated mAb with key suppliers and 
   developed reagents, optimised assay conditions needed for a commercial test, 
   and signed development and commercial deals in the key markets of China and the
   US. It has also expanded potential long-term income streams through royalty deals.
 * **Valuation:** Our DCF model has been updated to reflect timing of launch, market
   opportunity and commercial deals for the key markets of China and the US These
   revisions generated a risk-adjusted value of £15.9m for the test. Adding in the
   value of royalty agreements gives a sum-of-the-parts valuation of £23.0m.
 * **Risks:** Cizzle is a small company with limited resources. Development of a
   commercial test kit for lung and other cancers is dependent on the optimisation
   of the mAbs and reagents and validation in a small trial. Development and commercial
   deals in key territories have greatly reduced R&D costs and risks.
 * **Investment summary:** Since listing, Cizzle Biotechnology has delivered a stream
   of positive news, particularly the collaborations and strategic partnerships 
   that accelerate the number and magnitude of potential income streams. Delivery
   of the detector mAbs and reagents for the commercial test was a significant milestone,
   and triggers the development in China and the US. Despite this news, the shares
   are underappreciated, leaving the company trading on an EV of just £3.0m.

[DOWNLOAD THE FULL REPORT](https://hardmanandco.com/research/corporate-research/considerable-progress-in-first-year-since-listing/?dm_i=49CL,1D4D6,6NAI95,6B4AR,1#report-download)

Share on:
